Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations
Tumor necrosis factor α neutralization seems a rational therapy for myositis because this proinflammatory cytokine has been implicated in the pathogenesis of this disorder. Until now, we have treated 2 patients with a chimeric anti-TNF-α monoclonal antibody (infliximab). Both patients demonstrated a...
Gespeichert in:
| Veröffentlicht in: | European neurology 2003-01, Vol.50 (1), p.10-15 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 15 |
|---|---|
| container_issue | 1 |
| container_start_page | 10 |
| container_title | European neurology |
| container_volume | 50 |
| creator | Hengstman, G.J.D. van den Hoogen, F.H.J. Barrera, P. Netea, M.G. Pieterse, A. van de Putte, L.B.A. van Engelen, B.G.M. |
| description | Tumor necrosis factor α neutralization seems a rational therapy for myositis because this proinflammatory cytokine has been implicated in the pathogenesis of this disorder. Until now, we have treated 2 patients with a chimeric anti-TNF-α monoclonal antibody (infliximab). Both patients demonstrated a marked and sustained subjective and objective improvement without the occurrence of any side effects. These preliminary results suggest that anti-TNF-α treatment with infliximab is a safe and rapidly effective therapy for myositis. |
| doi_str_mv | 10.1159/000070852 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000070852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>370426011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-c63614d0bf2a9e0ed8fb2b7af45af7a3611a8f3c365958d0ca3dd6b3faf17f2e3</originalsourceid><addsrcrecordid>eNqF0d1rFDEQAPAgFnu2PvgsyCJU6MPafOxuNr4d9WqF0hY8n5fZ7MSm7m6uSbZ6_72pd1yLCOYlJPNjMpkh5DWjHxgr1QlNS9K65M_IjBWc5Uox8ZzMKGVFLijn--RlCLfpWCpZvyD7jNe8kLSakV9fJ60xBDP12dIjxAHHmDmTfUI_QHTD2gUbbchg7LJr1693Fz9tvMnmY7T5chqczy9R-xQK-RnomM7zfnUDH7Nrj70d7Ah-nV21Af09ROvGcEj2DPQBX233A_LtbLE8Pc8vrj5_OZ1f5LpgVcx1JSpWdLQ1HBRS7GrT8laCKUowElKQQW2EFlWpyrqjGkTXVa0wYJg0HMUBeb_Ju_LubsIQm8EGjX0PI7opNFIIVTPK_ws5VbQqpUzw3V_w1k1-TJ9omCqUTP0WCR1v0ENTgkfTrLwdUhMaRpuHoTW7oSX7dptwagfsHuV2SgkcbQEEDb3xMGobHl1RK0X5k8p-gP-OfgcWl4s_LzWrziT05p9oU8tvODy1AA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>194970223</pqid></control><display><type>article</type><title>Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations</title><source>Karger Journals</source><source>MEDLINE</source><creator>Hengstman, G.J.D. ; van den Hoogen, F.H.J. ; Barrera, P. ; Netea, M.G. ; Pieterse, A. ; van de Putte, L.B.A. ; van Engelen, B.G.M.</creator><creatorcontrib>Hengstman, G.J.D. ; van den Hoogen, F.H.J. ; Barrera, P. ; Netea, M.G. ; Pieterse, A. ; van de Putte, L.B.A. ; van Engelen, B.G.M.</creatorcontrib><description>Tumor necrosis factor α neutralization seems a rational therapy for myositis because this proinflammatory cytokine has been implicated in the pathogenesis of this disorder. Until now, we have treated 2 patients with a chimeric anti-TNF-α monoclonal antibody (infliximab). Both patients demonstrated a marked and sustained subjective and objective improvement without the occurrence of any side effects. These preliminary results suggest that anti-TNF-α treatment with infliximab is a safe and rapidly effective therapy for myositis.</description><identifier>ISSN: 0014-3022</identifier><identifier>EISSN: 1421-9913</identifier><identifier>DOI: 10.1159/000070852</identifier><identifier>PMID: 12824706</identifier><identifier>CODEN: EUNEAP</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adult ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Biopsy ; Creatine Kinase - blood ; Cytokines - blood ; Dermatomyositis - drug therapy ; Dermatomyositis - immunology ; Dermatomyositis - pathology ; Drug Administration Schedule ; Electromyography - drug effects ; Female ; Follow-Up Studies ; Humans ; Immunomodulators ; Infliximab ; Infusions, Intravenous ; Isometric Contraction - drug effects ; Medical sciences ; Middle Aged ; Muscle, Skeletal - pathology ; Original Paper ; Pharmacology. Drug treatments ; Polymyositis - drug therapy ; Polymyositis - immunology ; Polymyositis - pathology ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor Necrosis Factor-alpha - physiology</subject><ispartof>European neurology, 2003-01, Vol.50 (1), p.10-15</ispartof><rights>2003 S. Karger AG, Basel</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 S. Karger AG, Basel</rights><rights>Copyright S. Karger AG 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-c63614d0bf2a9e0ed8fb2b7af45af7a3611a8f3c365958d0ca3dd6b3faf17f2e3</citedby><cites>FETCH-LOGICAL-c416t-c63614d0bf2a9e0ed8fb2b7af45af7a3611a8f3c365958d0ca3dd6b3faf17f2e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14899027$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12824706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hengstman, G.J.D.</creatorcontrib><creatorcontrib>van den Hoogen, F.H.J.</creatorcontrib><creatorcontrib>Barrera, P.</creatorcontrib><creatorcontrib>Netea, M.G.</creatorcontrib><creatorcontrib>Pieterse, A.</creatorcontrib><creatorcontrib>van de Putte, L.B.A.</creatorcontrib><creatorcontrib>van Engelen, B.G.M.</creatorcontrib><title>Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations</title><title>European neurology</title><addtitle>Eur Neurol</addtitle><description>Tumor necrosis factor α neutralization seems a rational therapy for myositis because this proinflammatory cytokine has been implicated in the pathogenesis of this disorder. Until now, we have treated 2 patients with a chimeric anti-TNF-α monoclonal antibody (infliximab). Both patients demonstrated a marked and sustained subjective and objective improvement without the occurrence of any side effects. These preliminary results suggest that anti-TNF-α treatment with infliximab is a safe and rapidly effective therapy for myositis.</description><subject>Adult</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Creatine Kinase - blood</subject><subject>Cytokines - blood</subject><subject>Dermatomyositis - drug therapy</subject><subject>Dermatomyositis - immunology</subject><subject>Dermatomyositis - pathology</subject><subject>Drug Administration Schedule</subject><subject>Electromyography - drug effects</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Infliximab</subject><subject>Infusions, Intravenous</subject><subject>Isometric Contraction - drug effects</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Muscle, Skeletal - pathology</subject><subject>Original Paper</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymyositis - drug therapy</subject><subject>Polymyositis - immunology</subject><subject>Polymyositis - pathology</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor Necrosis Factor-alpha - physiology</subject><issn>0014-3022</issn><issn>1421-9913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0d1rFDEQAPAgFnu2PvgsyCJU6MPafOxuNr4d9WqF0hY8n5fZ7MSm7m6uSbZ6_72pd1yLCOYlJPNjMpkh5DWjHxgr1QlNS9K65M_IjBWc5Uox8ZzMKGVFLijn--RlCLfpWCpZvyD7jNe8kLSakV9fJ60xBDP12dIjxAHHmDmTfUI_QHTD2gUbbchg7LJr1693Fz9tvMnmY7T5chqczy9R-xQK-RnomM7zfnUDH7Nrj70d7Ah-nV21Af09ROvGcEj2DPQBX233A_LtbLE8Pc8vrj5_OZ1f5LpgVcx1JSpWdLQ1HBRS7GrT8laCKUowElKQQW2EFlWpyrqjGkTXVa0wYJg0HMUBeb_Ju_LubsIQm8EGjX0PI7opNFIIVTPK_ws5VbQqpUzw3V_w1k1-TJ9omCqUTP0WCR1v0ENTgkfTrLwdUhMaRpuHoTW7oSX7dptwagfsHuV2SgkcbQEEDb3xMGobHl1RK0X5k8p-gP-OfgcWl4s_LzWrziT05p9oU8tvODy1AA</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>Hengstman, G.J.D.</creator><creator>van den Hoogen, F.H.J.</creator><creator>Barrera, P.</creator><creator>Netea, M.G.</creator><creator>Pieterse, A.</creator><creator>van de Putte, L.B.A.</creator><creator>van Engelen, B.G.M.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20030101</creationdate><title>Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations</title><author>Hengstman, G.J.D. ; van den Hoogen, F.H.J. ; Barrera, P. ; Netea, M.G. ; Pieterse, A. ; van de Putte, L.B.A. ; van Engelen, B.G.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-c63614d0bf2a9e0ed8fb2b7af45af7a3611a8f3c365958d0ca3dd6b3faf17f2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Creatine Kinase - blood</topic><topic>Cytokines - blood</topic><topic>Dermatomyositis - drug therapy</topic><topic>Dermatomyositis - immunology</topic><topic>Dermatomyositis - pathology</topic><topic>Drug Administration Schedule</topic><topic>Electromyography - drug effects</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Infliximab</topic><topic>Infusions, Intravenous</topic><topic>Isometric Contraction - drug effects</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Muscle, Skeletal - pathology</topic><topic>Original Paper</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymyositis - drug therapy</topic><topic>Polymyositis - immunology</topic><topic>Polymyositis - pathology</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor Necrosis Factor-alpha - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hengstman, G.J.D.</creatorcontrib><creatorcontrib>van den Hoogen, F.H.J.</creatorcontrib><creatorcontrib>Barrera, P.</creatorcontrib><creatorcontrib>Netea, M.G.</creatorcontrib><creatorcontrib>Pieterse, A.</creatorcontrib><creatorcontrib>van de Putte, L.B.A.</creatorcontrib><creatorcontrib>van Engelen, B.G.M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>European neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hengstman, G.J.D.</au><au>van den Hoogen, F.H.J.</au><au>Barrera, P.</au><au>Netea, M.G.</au><au>Pieterse, A.</au><au>van de Putte, L.B.A.</au><au>van Engelen, B.G.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations</atitle><jtitle>European neurology</jtitle><addtitle>Eur Neurol</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>50</volume><issue>1</issue><spage>10</spage><epage>15</epage><pages>10-15</pages><issn>0014-3022</issn><eissn>1421-9913</eissn><coden>EUNEAP</coden><abstract>Tumor necrosis factor α neutralization seems a rational therapy for myositis because this proinflammatory cytokine has been implicated in the pathogenesis of this disorder. Until now, we have treated 2 patients with a chimeric anti-TNF-α monoclonal antibody (infliximab). Both patients demonstrated a marked and sustained subjective and objective improvement without the occurrence of any side effects. These preliminary results suggest that anti-TNF-α treatment with infliximab is a safe and rapidly effective therapy for myositis.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>12824706</pmid><doi>10.1159/000070852</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-3022 |
| ispartof | European neurology, 2003-01, Vol.50 (1), p.10-15 |
| issn | 0014-3022 1421-9913 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000070852 |
| source | Karger Journals; MEDLINE |
| subjects | Adult Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Biological and medical sciences Biopsy Creatine Kinase - blood Cytokines - blood Dermatomyositis - drug therapy Dermatomyositis - immunology Dermatomyositis - pathology Drug Administration Schedule Electromyography - drug effects Female Follow-Up Studies Humans Immunomodulators Infliximab Infusions, Intravenous Isometric Contraction - drug effects Medical sciences Middle Aged Muscle, Skeletal - pathology Original Paper Pharmacology. Drug treatments Polymyositis - drug therapy Polymyositis - immunology Polymyositis - pathology Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - physiology |
| title | Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A41%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20Treatment%20of%20Dermatomyositis%20and%20Polymyositis%20with%20Anti-Tumor-Necrosis-Factor-Alpha:%20Preliminary%20Observations&rft.jtitle=European%20neurology&rft.au=Hengstman,%20G.J.D.&rft.date=2003-01-01&rft.volume=50&rft.issue=1&rft.spage=10&rft.epage=15&rft.pages=10-15&rft.issn=0014-3022&rft.eissn=1421-9913&rft.coden=EUNEAP&rft_id=info:doi/10.1159/000070852&rft_dat=%3Cproquest_cross%3E370426011%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=194970223&rft_id=info:pmid/12824706&rfr_iscdi=true |